AstraZeneca Sheds Rights to Three Respiratory Drugs for $350M

15:00 EST 7 Nov 2018 | Drug Discovery Development

News
AstraZeneca has entered into an agreement with Covis Pharma B.V. to sell its rights for asthma drug Alvesco and rhinitis medications Omnaris and Zetonna.
Staff Author: 
Mike Botta
Topics: 
Supply Chain

Original Article: AstraZeneca Sheds Rights to Three Respiratory Drugs for $350M

More From BioPortfolio on "AstraZeneca Sheds Rights to Three Respiratory Drugs for $350M"